R B Kim

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren
    R B Kim
    Department of Pharmacology, Vanderbilt University, Nashville, TN 37232 6600, USA
    Biochim Biophys Acta 1328:41-7. 1997
  2. ncbi Identification of functionally variant MDR1 alleles among European Americans and African Americans
    R B Kim
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Pharmacol Ther 70:189-99. 2001
  3. ncbi Transporters and xenobiotic disposition
    Richard B Kim
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, 572 RRB1, 23rd Avenue at Pierce Avenue, Nashville, TN 37323 6602, USA
    Toxicology 181:291-7. 2002
  4. ncbi Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity
    R B Kim
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6600, USA
    J Pharmacol Exp Ther 291:1204-9. 1999
  5. ncbi Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
    R B Kim
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    Pharm Res 16:408-14. 1999
  6. ncbi Drugs as P-glycoprotein substrates, inhibitors, and inducers
    Richard B Kim
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    Drug Metab Rev 34:47-54. 2002
  7. ncbi Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
    R G Tirona
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Biol Chem 276:35669-75. 2001
  8. ncbi Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2
    M Jisaka
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Biol Chem 275:1287-93. 2000
  9. ncbi The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization
    V Dishy
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    N Engl J Med 345:1030-5. 2001
  10. ncbi Intestinal drug transporter expression and the impact of grapefruit juice in humans
    H Glaeser
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 81:362-70. 2007

Detail Information

Publications80

  1. ncbi High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren
    R B Kim
    Department of Pharmacology, Vanderbilt University, Nashville, TN 37232 6600, USA
    Biochim Biophys Acta 1328:41-7. 1997
    ..Collectively, these data suggest the presence of a novel high affinity, low capacity transporter in rat hepatocytes with specific affinity for ditekiren and possibly other oligopeptides...
  2. ncbi Identification of functionally variant MDR1 alleles among European Americans and African Americans
    R B Kim
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Pharmacol Ther 70:189-99. 2001
    ..Thus allelic variation in MDR1 is more common than previously recognized and involves multiple SNPs whose allelic frequencies vary between populations, and some of these SNPs are associated with altered P-glycoprotein function...
  3. ncbi Transporters and xenobiotic disposition
    Richard B Kim
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, 572 RRB1, 23rd Avenue at Pierce Avenue, Nashville, TN 37323 6602, USA
    Toxicology 181:291-7. 2002
    ..Accordingly, this review will outline relevant background information regarding drug transporters and the role of such transporters in the drug disposition process...
  4. ncbi Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity
    R B Kim
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6600, USA
    J Pharmacol Exp Ther 291:1204-9. 1999
    ....
  5. ncbi Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
    R B Kim
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    Pharm Res 16:408-14. 1999
    ..In order to test this notion more fully, systematic studies were undertaken to determine the P-gp-mediated transport and inhibitory characteristics of prototypical CYP substrates...
  6. ncbi Drugs as P-glycoprotein substrates, inhibitors, and inducers
    Richard B Kim
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    Drug Metab Rev 34:47-54. 2002
  7. ncbi Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
    R G Tirona
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Biol Chem 276:35669-75. 2001
    ....
  8. ncbi Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2
    M Jisaka
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Biol Chem 275:1287-93. 2000
    ..Thus, this positional determinant of the 8-LOX and 15-LOX-2 may have significance for other lipoxygenases...
  9. ncbi The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization
    V Dishy
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    N Engl J Med 345:1030-5. 2001
    ..Therefore, polymorphisms of the beta2-adrenergic receptor are potentially important determinants of the vascular response to stress...
  10. ncbi Intestinal drug transporter expression and the impact of grapefruit juice in humans
    H Glaeser
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 81:362-70. 2007
    ..Although short-term grapefruit juice ingestion was associated with reduced fexofenadine availability, OATP1A2 or MDR1 expression was unaffected...
  11. ncbi In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism
    G Sofowora
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    Pharmacogenetics 11:809-14. 2001
    ..This polymorphism may only have clinical significance in the presence of endothelial dysfunction...
  12. ncbi Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants
    M F Fromm
    Division of Clinical Pharmacology, 572 Medical Research Bldg 1, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232 6602, USA
    Biochim Biophys Acta 1415:369-74. 1999
    ..In addition, MRP3 genomic organization including the 5'-flanking region and a major portion of the MRP3 intron-exon organization are identified and characterized...
  13. ncbi Site-directed mutagenesis studies on a putative fifth iron ligand of mouse 8S-lipoxygenase: retention of catalytic activity on mutation of serine-558 to asparagine, histidine, or alanine
    M Jisaka
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    Arch Biochem Biophys 386:136-42. 2001
    ..We conclude that mouse 8-LOX is catalytically competent with only four amino acid iron ligands, and that Ser-558 of the wild-type enzyme does not play an essential role in catalysis...
  14. ncbi In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna
    M J Cutler
    Department of Medicine, Division of Clinical Pharmacology, The University of Western Ontario, London, Ontario, Canada
    J Clin Pharmacol 52:530-42. 2012
    ..Loss of renal transporter function due to genetic variability or drug-drug interactions may decrease the efficacy of chemoprotectants, increasing the risk of ifosfamide- and cisplatin-induced toxicities...
  15. ncbi Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects
    C M Stein
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Pharmacol Ther 69:317-23. 2001
    ..Pharmacodynamic responses to cyclosporine have not been compared among ethnic groups...
  16. ncbi A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade
    G G Sofowora
    Division of Clinival Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 373232 6602, USA
    Clin Pharmacol Ther 73:366-71. 2003
    ..A common polymorphism of the beta(1)-adrenergic receptor Arg389Gly markedly affects function in vitro, but little is known about its in vivo significance...
  17. ncbi Molecular basis of ethnic differences in drug disposition and response
    H G Xie
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    Annu Rev Pharmacol Toxicol 41:815-50. 2001
    ..A better understanding of the molecular basis underlying ethnic differences in drug metabolism, transport, and response will contribute to improved individualization of drug therapy...
  18. ncbi A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression
    W E Boeglin
    Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232 6602, USA
    Proc Natl Acad Sci U S A 95:6744-9. 1998
    ..5-kilobase mRNA by Northern analysis of keratinocytes. Identification of this enzyme extends the known distribution of R-lipoxygenases to humans and presents an additional target for potential therapeutic interventions in psoriasis...
  19. ncbi Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo
    H G Xie
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Pharmacogenetics 11:191-7. 2001
    ....
  20. ncbi Organic anion-transporting polypeptide (OATP) transporter family and drug disposition
    R B Kim
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Eur J Clin Invest 33:1-5. 2003
    ....
  21. ncbi Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin
    M Jisaka
    Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Biol Chem 272:24410-6. 1997
    ..The inducibility may be a characteristic feature of the mouse 8S-lipoxygenase and its human 15S-lipoxygenase homologue...
  22. ncbi Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics
    David A Katz
    Department of Pharmacogenetics, Abbott Laboratories, Abbott Park, IL 60064, USA
    Clin Pharmacol Ther 79:186-96. 2006
    ..Our objective was to learn whether genetic polymorphisms of metabolic enzymes or transport proteins provide a mechanistic understanding of the in vivo disposition of atrasentan, a selective endothelin A receptor antagonist...
  23. ncbi Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  24. ncbi Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
    David W Haas
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 192:1931-42. 2005
    ..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment...
  25. ncbi Transporters and drug therapy: implications for drug disposition and disease
    Richard H Ho
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Pharmacol Ther 78:260-77. 2005
    ....
  26. ncbi St John's wort-associated drug interactions: short-term inhibition and long-term induction?
    Hong Guang Xie
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232 6602, USA
    Clin Pharmacol Ther 78:19-24. 2005
  27. ncbi Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula
    Haibo Xu
    Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8
    Br J Pharmacol 146:296-305. 2005
    ..In conclusion, infant formula, but not human milk, enhances in vitro CYP1A expression via an AhR-mediated pathway, providing a potential mechanistic basis for the increased caffeine elimination in formula-fed infants...
  28. ncbi Grapefruit juice ingestion significantly reduces talinolol bioavailability
    Ute I Schwarz
    Institute of Clinical Pharmacology, Medical Faculty, Technical University, and Medical Department I, Technical University Hospital, Dresden
    Clin Pharmacol Ther 77:291-301. 2005
    ....
  29. ncbi Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides
    George K Dresser
    Lawson Health Research Institute, London Health Sciences Centre, UK
    Clin Pharmacol Ther 77:170-7. 2005
    ..A much higher volume caused an additional modest effect, possibly from reduced intestinal concentration and transit time of fexofenadine. This food-drug interaction appears to be novel and may be relevant to other fruit juices and drugs...
  30. ncbi Hepatic uptake of the novel antifungal agent caspofungin
    Punam Sandhu
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    Drug Metab Dispos 33:676-82. 2005
    ..Taken together, these findings suggest that OATP1B1-mediated hepatic uptake may contribute to the overall elimination of this drug from the body...
  31. ncbi Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development
    Wooin Lee
    Department of Medicine, Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Oncologist 10:104-11. 2005
    ..This review discusses the current and future applications of pharmacogenomics in clinical cancer therapy and cancer drug development...
  32. ncbi Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse
    Catherine L Booth-Genthe
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    J Pharmacol Toxicol Methods 54:78-89. 2006
    ..Here, we describe the development and characterization of LLC-PK1 cells expressing rat Abcb1...
  33. ncbi Transporter-mediated protection against thiopurine-induced hematopoietic toxicity
    Partha Krishnamurthy
    Department of Pharmaceutical Sciences and Animal Resource Center, St Jude Children s Research Hospital, Memphis, Tenessee 38105, USA
    Cancer Res 68:4983-9. 2008
    ..This SNP is common (>18%) in the Japanese population and indicates that the increased sensitivity of some Japanese patients to thiopurines may reflect the greater frequency of this MRP4 SNP...
  34. ncbi Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2)
    Ulrike Gradhand
    Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
    Drug Metab Rev 40:317-54. 2008
    ....
  35. ncbi Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe
    Bradley L Urquhart
    Division of Clinical Pharmacology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
    Pharmacogenet Genomics 18:439-48. 2008
    ..Accordingly, sulfasalazine may prove to have utility as in vivo probe for assessing the clinical impact of BCRP for the disposition and efficacy of drugs...
  36. ncbi Genetic determinants of response to warfarin during initial anticoagulation
    Ute I Schwarz
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, USA
    N Engl J Med 358:999-1008. 2008
    ....
  37. ncbi A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor
    Christine Healan-Greenberg
    Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064 6104, USA
    Drug Metab Dispos 36:500-7. 2008
    ..Among the class of HIV-PIs, which are typically PXR activators, A-792611 seems to have a unique property for PXR antagonism and could be a useful tool for studying nuclear receptor pathway regulation...
  38. ncbi Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
    Richard H Ho
    Department of Pediatrics and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Pharmacogenet Genomics 17:647-56. 2007
    ....
  39. ncbi A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression
    Catia Marzolini
    Division of Clinical Pharmacology, Department of Medicine, The University of Western Ontario, London Health Sciences Centre, University Hospital, London, Ontario, Canada N6A 5A5
    Mol Endocrinol 21:1769-80. 2007
    ..These findings are the first to identify the presence of a common genetic variant in FXR with functional consequences that could contribute to disease risk or therapeutic outcomes...
  40. ncbi Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes
    Peter J Mohler
    Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, USA
    Circulation 115:432-41. 2007
    ..More importantly, there is no cellular explanation for the range of severity of cardiac phenotypes associated with specific ANK2 variants...
  41. ncbi Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
    Catia Marzolini
    Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232, USA
    Clin Pharmacol Ther 75:13-33. 2004
    ..In addition, issues relating to MDR1 haplotypes, environmental factors, and study design, as potential confounding factors of the observed MDR1 polymorphism effect in vivo, are also discussed...
  42. ncbi Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study
    Alison A Motsinger
    Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Pharmacogenet Genomics 16:837-45. 2006
    ..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms...
  43. ncbi Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition
    Ute I Schwarz
    Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Br J Clin Pharmacol 62:485-91. 2006
    ....
  44. ncbi Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration
    David W Haas
    Microbiology and Immunology, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Clin Infect Dis 43:783-6. 2006
    ..Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016)...
  45. ncbi Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity
    Marylyn D Ritchie
    Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Infect Dis 43:779-82. 2006
    ..Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001)...
  46. ncbi Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes
    Mary Peace McRae
    School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA
    J Pharmacol Exp Ther 318:1068-75. 2006
    ..Nevirapine (75 microM) had no effect on bile acid transport in any model system. In conclusion, ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibited both the hepatic uptake and biliary excretion of taurocholate...
  47. ncbi Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry
    Wooin Lee
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University, Nashville Tennessee 37232, USA
    J Biol Chem 280:9610-7. 2005
    ..Taken together, these data suggest that SLCO1A2 polymorphisms may be an important yet unrecognized contributor to inter-individual variability in drug disposition and central nervous system entry of substrate drugs...
  48. ncbi Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
    David W Haas
    Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
    AIDS 18:2391-400. 2004
    ..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics...
  49. ncbi Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
    George K Dresser
    Department of Medicine, University of Western Ontario, London, Ontario, Canada
    Clin Pharmacol Ther 71:11-20. 2002
    ..Results support a new model of intestinal drug absorption and mechanism of food-drug interaction...
  50. ncbi "Inactive" excipients such as Cremophor can affect in vivo drug disposition
    Cristoph Wandel
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    Clin Pharmacol Ther 73:394-6. 2003
  51. ncbi MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences
    Richard B Kim
    Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, USA
    Pharmacogenetics 12:425-7. 2002
  52. ncbi Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis
    Yi-Min Zheng
    Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA
    Toxicol Appl Pharmacol 186:119-26. 2003
    ..These data provide additional evidence for the importance of this meander region Pro-X-Arg motif in CYP4B1 heme binding and catalytic function...
  53. ncbi Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
    Harumi Takahashi
    Department of Pharmacotherapy, Meiji Pharmaceutical University, Noshio 2 522 1, Kiyose, Tokyo 204 8588, Japan
    Clin Pharmacol Ther 73:253-63. 2003
    ....
  54. ncbi Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects
    George K Dresser
    Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Pharmacol Ther 73:41-50. 2003
    ..However, the relative contributions of enhanced metabolism and efflux transport to the overall induction process are unknown...
  55. ncbi The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
    Rommel G Tirona
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Nat Med 9:220-4. 2003
    ..These data identify HNF4alpha as an important regulator of coordinate nuclear-receptor-mediated response to xenobiotics...
  56. ncbi Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
    Rommel G Tirona
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Pharmacol Exp Ther 304:223-8. 2003
    ..This is the first demonstration of an uptake transporter such as OATP-C, in modulating PXR function, and sheds important new insight into our understanding of the molecular determinants of PXR-mediated inductive processes...
  57. ncbi Pharmacogenomics of organic anion-transporting polypeptides (OATP)
    Rommel G Tirona
    Division of Clinical Pharmacology, Department of Medicine, 572 RRB-1, 23rd Ave @ Pierce Ave, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    Adv Drug Deliv Rev 54:1343-52. 2002
    ..In this article, we review the molecular, biochemical and pharmacological aspects of known human OATPs including the presence and functional relevance of genetic polymorphisms...
  58. ncbi CYP2C9 allelic variants: ethnic distribution and functional significance
    Hong Guang Xie
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6602, USA
    Adv Drug Deliv Rev 54:1257-70. 2002
    ..In addition, possible molecular mechanisms underlying ethnic variability in the metabolism of CYP2C9 substrate drugs are discussed...
  59. ncbi MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients
    Thomas Illmer
    Medical Clinic and Polyclinic I, University Hospital of the Technical University, 01307 Dresden, Germany
    Cancer Res 62:4955-62. 2002
    ....
  60. ncbi Drug transporters in HIV Therapy
    Richard B Kim
    Division of Clinical Pharmacology at Vanderbilt University School of Medicine, Nashville, TN, USA
    Top HIV Med 11:136-9. 2003
    ..This article summarizes a presentation given by Richard B. Kim, MD, at the March 2003 International AIDS Society-USA course in Atlanta...
  61. ncbi Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy
    A Craig Lockhart
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Mol Cancer Ther 2:685-98. 2003
    ..The role of these transporters and their naturally occurring genetic polymorphisms in cancer and chemotherapy is reviewed...
  62. ncbi P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide
    Keith A Hoffmaster
    Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Pharm Res 21:1294-302. 2004
    ..CONCLUSIONS: These studies indicate that SC hepatocytes repolarize and traffic functional canalicular transport proteins to the appropriate cellular domain...
  63. ncbi The anthelminthic agent albendazole does not interact with p-glycoprotein
    Gracia Merino
    Department of Physiology, Faculty of Veterinary, University of Leon, Leon, Spain
    Drug Metab Dispos 30:365-9. 2002
    ..In conclusion, albendazole is neither a substrate nor an inhibitor of P-glycoprotein. Therefore, interactions between albendazole and P-glycoprotein substrates or inhibitors are unlikely to be clinically important...
  64. ncbi 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?
    Richard B Kim
    Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Pharmacol Ther 75:381-5. 2004
  65. ncbi Pharmacogenomics of the OATP and OAT families
    Catia Marzolini
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Pharmacogenomics 5:273-82. 2004
    ..In this review, recent progress relating to pharmacogenomics of organic anion transporters will be outlined along with a compilation of currently known genetic polymorphisms...
  66. ncbi Genetic variability in CYP3A5 and its possible consequences
    Hong Guang Xie
    Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Pharmacogenomics 5:243-72. 2004
    ....
  67. ncbi Transporters and renal drug elimination
    Wooin Lee
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA
    Annu Rev Pharmacol Toxicol 44:137-66. 2004
    ..In this review, we summarize recent progress in terms of molecular and functional characterization of renal transporters and their clinical relevance to drug therapy...
  68. ncbi Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome
    Hideaki Kanki
    Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    J Cardiovasc Electrophysiol 13:252-6. 2002
    ....
  69. ncbi Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition
    Richard H Ho
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    J Biol Chem 279:7213-22. 2004
    ..Accordingly, our study indicates functionally important polymorphisms in NTCP exist and that the likelihood of being carriers of such polymorphisms is dependent on ethnicity...
  70. ncbi MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study
    David W Haas
    Division of Infectious Diseases, Vanderbilt University School of Medicine, 345 24th Avenue, North, Suite 105, Nashville, TN 37212, USA
    J Acquir Immune Defic Syndr 34:295-8. 2003
    ..It is concluded with 95% confidence that phase 1 viral decay differences between exon 26 TT and CC groups are unlikely to exceed 18%...
  71. ncbi Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
    Michael D Floyd
    Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6602, USA
    Pharmacogenetics 13:595-606. 2003
    ..In most healthy subjects, variability in intestinal and hepatic CYP3A activity, using midazolam as an in-vivo probe, is modest and common polymorphisms in CYP3A4 and CYP3A5 do not appear to have important functional significance...
  72. ncbi Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances
    Richard B Kim
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Adv Drug Deliv Rev 54:1241-2. 2002
  73. ncbi Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates
    Sean Ekins
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Indiana, USA
    Mol Pharmacol 61:974-81. 2002
    ..These 3D-QSAR models will be useful for future prediction of likely substrates and inhibitors of P-gp...
  74. ncbi Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs
    Bradley L Urquhart
    Division of Clinical Pharmacology, London Health Sciences Centre University Hospital, Room ALL 152, 339 Windermere Road, London, Ontario N6A 5A5, Canada
    J Clin Pharmacol 47:566-78. 2007
    ..Finally, they outline how the drug development process has been affected by the current understanding of the involvement of nuclear receptors in the regulation of drug disposition genes...
  75. ncbi Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics
    Richard H Ho
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Gastroenterology 130:1793-806. 2006
    ..Accordingly, transporter expression and polymorphisms may be key determinants of intersubject variability in response to statin therapy in general...
  76. ncbi Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier
    Edna F Choo
    Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA
    J Pharmacol Exp Ther 317:1012-8. 2006
    ..Such resistance can be overcome by a sufficiently high dose of an inhibitor; however, whether this is safely attainable in the clinical situation remains to be determined...
  77. ncbi Beyond CAR and PXR
    Santosh G Dixit
    College of Pharmacy, University of Cincinnati Medical Center, Ohio, USA
    Curr Drug Metab 6:385-97. 2005
    ..In this review, the biology, pathophysiology, and the potential clinical relevance of such NRs to drug disposition and response are discussed...
  78. ncbi Placental transfer of antiretroviral drugs
    Catia Marzolini
    Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232, USA
    Clin Pharmacol Ther 78:118-22. 2005
  79. ncbi Alpha 1A-adrenergic receptor polymorphism and vascular response
    Gbenga G Sofowora
    Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Pharmacol Ther 75:539-45. 2004
    ..Variability in sensitivity to phenylephrine, an alpha(1A) adrenergic agonist, has a large genetic component. We examined the hypothesis that a common polymorphism of alpha(1A)-adrenergic receptor (Arg347Cys) affects in vivo response...
  80. ncbi Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor
    Xianghai Chen
    Faculty of Pharmacy, University of Toronto, 19 Russell Street, Toronto, Ontario M5S 2S2, Canada
    Mol Pharmacol 69:1913-23. 2006
    ..Human ABST mRNA and promoter activity were also increased in Caco-2 cells treated with 1,25(OH)(2)D(3), suggesting a physiological role of VDR in human ileal bile acid homeostasis...